Months after the FDA sanctioned the approval of Roche’s runner up checkpoint inhibitor Tecentriq in mixture with Celgene’s Abraxane for treatment-naive patients with triple-negative breast cancer, Merck’s keynote…

Up to 70% of breast cancer survivors who have had mastectomies are uncertain or unaware of their reconstruction alternatives. The Alliance in Reconstructive Surgery (AiRS) Foundation is a…

A new most cancers look at made headlines this week as researchers found that a low-fat weight-reduction plan allows reducing the threat of loss of life from breast…